Genomics

Dataset Information

0

MiRNA signatures underly chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR

ABSTRACT: Chemotherapy resistance is a major clinical issue for pancreatic adenocarcinoma (PDAC). MicroRNAs (miRNAs) play an important role in cancer progression and chemoresistance. In this study, we addressed the association between miRNA expression profiles and gemcitabine (Gem) resistance. A Gem sensitive (GS) PDAC cancer cell line, MIA PaCa-2, and its Gem resistant (GR) progeny MIA PaCa-2 GR, was used to determine miRNA expression changes by resistance to Gemcitabine. miRNA-seq was used to determine the miRNA expression profiles in these cell lines. Ingenuity Pathway Analysis (IPA) was performed to determine the biological functions of differentially expressed miRNAs. In total, 1867 miRNAs were detected in the two cell lines. We found that the miRNA expression profiles were different between the GR and its sensitive isogenic parental GS cell line, and certain differentially expressed miRNAs were only detected in one or the other of these PDAC cell lines. A total of 97 (5.2%) miRNAs were significantly differentially expressed between GR and the GS cell lines, of which 65 (3.5%) miRNAs were upregulated and 32 (1.7%) miRNAs were downregulated. The miRNAs with the most significant differential expression in the GR cell line as compared with GS were primarily involved in the following biological processes: cell proliferation, cell migration & invasion, chemo-sensitization, alternative splicing, apoptosis, and angiogenesis. These miRNAs from cell lines were further refined to a subset and were analyzed in patient samples where expression was used to identify patients with recurrent tumors. Taken together, the results suggest that these miRNAs may play important roles in Gem resistance in PDAC. This study’s findings provides a basis for further research in the diagnosis and treatment selection for PDACs with gemcitabine resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE269190 | GEO | 2024/07/01

REPOSITORIES: GEO

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

Transcriptomics mRNA Expression profiles of parental Panc cell lines and Gemcitabine resistance Panc1cell lines
2016-04-26 | GSE80617 | GEO
Genomics The miRNA profiling in PANC-1, PANC-1 GEM 100 and PANC-1 GEM1500 cells
2016-12-31 | GSE79234 | GEO
Genomics microRNA Expression profiles of parental Panc1 cell lines and Gemcitabine resistance Panc1 cell lines
2016-04-26 | GSE80616 | GEO
Transcriptomics Transcriptome analysis of human pancreatic cancer cell lines and gemcitabine-resistant pancreatic cancer cell lines
2020-02-10 | GSE140077 | GEO
Proteomics A pancreatic cancer cells spectral library and the phenotype analysis of gemcitabine-sensitive and -resistant pancreatic cell lines by the data-independent acquisition proteome strategy
2022-05-31 | PXD030948 | Pride
Transcriptomics High-throughput RNA sequencing on circular RNA profiles of human pancreatic cancer cell lines and gemcitabine resistant pancreatic cancer cell lines.
2019-07-07 | GSE110580 | GEO
Transcriptomics MicroRNA screening in human pancreatic carcinoma cell lines
2015-11-03 | E-GEOD-74565 | biostudies-arrayexpress
Transcriptomics Profiling the Panc1 pancreatic cancer cell line following Gemcitabine treatment using single cell RNA sequencing
2022-03-21 | GSE186960 | GEO
Proteomics Highly-reproducible quantitative proteomics analysis of pancreatic cancer cells reveals proteome-level effects of a novel combination drug therapy that induces cancer cell death via metabolic remodeling and activation of the extrinsic apoptosis pathway
2024-11-19 | PXD044149 | Pride
Methylation profiling N6-methyladenosine-enhanced FZR1 translation contributes to gemcitabine insensitivity in pancreatic cancer via quiescence maintenance [m6A-seq]
2023-06-09 | GSE206968 | GEO